Komori
Earnings presentation4503Astellas Pharma Inc.Pharmaceuticals

Supplementary Financial Results Materials for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027

In the interim period of fiscal 2027, revenue and profit exceeded the year-earlier period, and the full-year forecasts for revenue, operating profit and interim profit, among others, were revised upward. For products in development, the disclosure also lists new regulatory filings and entries into clinical trials, as well as several development discontinuations.

Worth reading
68In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
1172
¥100 million (year-on-year increase in full-basis operating profit)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportSecond quarter (interim period) of the fiscal year ending March 20278 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥12,709 100 million+23.4%
Operating profit¥3,166 100 million +58.8%full basis
Ordinary income¥3,175 100 million +63.1%IFRS interim profit before tax
Net income¥2,415 100 million +63.6%interim profit
Selling, general and administrative expenses¥4,304 100 million
Operating profit margin
Rate24.9% (full basis)
Results for the three months of the current quarter
April-June
Revenue
¥6,409 100 million+26.7%
Operating profit
¥1,845 100 million +94.9%full basis
Quarterly profit
¥1,418 100 million+107.2%
July-September
Revenue
¥6,299 100 million+20.1%
Operating profit
¥1,321 100 million +26.1%full basis
Quarterly profit
¥998 100 million+26.0%
Full-year earnings forecast
Revenue
¥23,300 100 million
Operating profit
¥4,600 100 million full basis
Interim profit
¥3,500 100 million
Core operating profit
¥7,000 100 million
Core interim profit
¥5,200 100 million
Capital expenditures
¥550 100 million
Annual Dividend
80 yen
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Fluctuations in foreign exchange rates
Revenue
¥993 100 million
Core operating profit
¥412 100 million
Major product sales
Total priority strategic products
¥1,134 100 million
XTANDI
¥567 100 million
Betanis, Myrbetriq, Betmiga
¥330 100 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
USD/JPY
Actual results159
Full-year forecast158
EUR/JPY
Actual results184
Full-year forecast181
New initiatives
  • European approval obtained for PADCEV
  • Regulatory filings for fezolinetant in Japan and China
  • ASP2138 advanced to Phase 3
  • ASP388B entered Phase 1
  • setidegrasib advanced to Phase 3 for non-small cell lung cancer
  • ASP2020 entered Phase 1
Key KPIsA metric the company considers important as a management benchmark.
Revenue from key strategic products
¥3,339 100 million+51.4%
PADCEV revenue
¥1,583 100 million+54.5%
IZERVAY revenue
¥562 100 million+64.5%
VYLOY revenue
¥459 100 million+72.7%
VEOZAH revenue
¥307 100 million+33.8%
XOSPATA revenue
¥429 100 million+24.5%
XTANDI revenue
¥5,337 100 million+11.9%
Prograf revenue
¥1,143 100 million+10.8%
Segment results
United States
Revenue
¥5,768 100 million+26.2%
Japan
Revenue
¥1,608 100 million+12.5%
Established Markets
Revenue
¥3,040 100 million+14.8%
China
Revenue
¥689 100 million+38.5%
International Markets
Revenue
¥1,542 100 million+38.2%
Number of employees
Number of Employees14,290 people
Capital expenditures
¥227 100 million
Annual Dividend
Annual dividend per share80 yen
Interim40 yen
End of period40 yen
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings report
Fiscal Period CoveredSecond quarter (interim period) of the fiscal year ending March 2027
Net Sales¥12,709 100 million (YoY +23.4%)
Operating profit¥3,166 100 million (full basis) (YoY +58.8%)
Ordinary income¥3,175 100 million (IFRS interim profit before tax) (YoY +63.1%)
Net income¥2,415 100 million (interim profit) (YoY +63.6%)
Operating profit marginRate 24.9% (full basis) / Year-on-year change (points) Not disclosed
Selling, general and administrative expenses¥4,304 100 million
Results for the three months of the current quarterApril-June Revenue ¥6,409 100 million (YoY +26.7%) / Operating profit ¥1,845 100 million (full basis) (YoY +94.9%) / Quarterly profit ¥1,418 100 million (YoY +107.2%) / July-September Revenue ¥6,299 100 million (YoY +20.1%) / Operating profit ¥1,321 100 million (full basis) (YoY +26.1%) / Quarterly profit ¥998 100 million (YoY +26.0%)
Full-year earnings forecastRevenue ¥23,300 100 million / Operating profit ¥4,600 100 million (full basis) / Interim profit ¥3,500 100 million / Core operating profit ¥7,000 100 million / Core interim profit ¥5,200 100 million / Capital expenditures ¥550 100 million / Annual Dividend 80 yen
Segment resultsUnited States Revenue ¥5,768 100 million (YoY +26.2%) / Japan Revenue ¥1,608 100 million (YoY +12.5%) / Established Markets Revenue ¥3,040 100 million (YoY +14.8%) / China Revenue ¥689 100 million (YoY +38.5%) / International Markets Revenue ¥1,542 100 million (YoY +38.2%)
Breakdown of Factors Affecting the ChangeFluctuations in foreign exchange rates Revenue ¥993 100 million / Core operating profit ¥412 100 million / Major product sales Total priority strategic products ¥1,134 100 million / XTANDI ¥567 100 million / Betanis, Myrbetriq, Betmiga ¥330 100 million
Key KPIsRevenue from key strategic products ¥3,339 100 million (YoY +51.4%) / PADCEV revenue ¥1,583 100 million (YoY +54.5%) / IZERVAY revenue ¥562 100 million (YoY +64.5%) / VYLOY revenue ¥459 100 million (YoY +72.7%) / VEOZAH revenue ¥307 100 million (YoY +33.8%) / XOSPATA revenue ¥429 100 million (YoY +24.5%) / XTANDI revenue ¥5,337 100 million (YoY +11.9%) / Prograf revenue ¥1,143 100 million (YoY +10.8%)
Number of employeesNumber of Employees 14,290 people / Change during the period Not disclosed / Hiring plan Not disclosed
Assumptions Underlying the Business OutlookUSD/JPY Actual results 159 / Full-year forecast 158 / EUR/JPY Actual results 184 / Full-year forecast 181
Annual DividendAnnual dividend per share 80 yen / Interim 40 yen / End of period 40 yen
Capital expenditures¥227 100 million
New initiativesEuropean approval obtained for PADCEV, Regulatory filings for fezolinetant in Japan and China, ASP2138 advanced to Phase 3, ASP388B entered Phase 1, setidegrasib advanced to Phase 3 for non-small cell lung cancer, ASP2020 entered Phase 1
Items this document does not state (13)
Gross Profit MarginProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Revenue increased, driven by growth in sales of key strategic products and other products. In addition, exchange-rate movements increased revenue by ¥99.3 billion and core operating profit by ¥41.2 billion.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.